J. Varigos

发表

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

S. Yusuf, Li-sheng Liu, P. Pais, 2004, The Lancet.

ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction

R. Collins, M. Keltai, B. Lewis, 1995, The Lancet.

Do patients with heart failure appropriately undergo invasive procedures post‐myocardial infarction? Results from a prospective multicentre study

J. Varigos, B. Billah, H. Krum, 2008, Internal medicine journal.

Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.

S. Yusuf, J. Varigos, A. Tonkin, 2021, International journal of cardiology.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Khalid Yusoff, Frederick M. Costello, Martin O'Donnell, 2017, Lancet.

Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2018 .

Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study

J. Varigos, B. Billah, H. Krum, 2006 .

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis, M. Landray, R. Collins, 2022, The Lancet.

Effect of potentially modiﬁable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

S. Yusuf, J. Varigos, A. Budaj, 2022 .

ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION

David Hunt, P Armitage, Sarah Parish, 1992 .

Primary course immunogenicity and reactogenicity of a new diphtheria‐tetanus‐whole cell pertussis vaccine (DTPw)

J. Varigos, T. Nolan, G. Hogg, 1997, Journal of paediatrics and child health.

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.

J. Le Heuzey, M. Pfeffer, S. Yusuf, 2006, American heart journal.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

R. Collins, S. Cosgrove, P. Libby, 2017, The Lancet.

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline

Eric E. Smith, Deepak L. Bhatt, S. Yusuf, 2020, Stroke.

Stroke Outcomes in the COMPASS Trial

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2019, Circulation.

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial

Eric E. Smith, Deepak L. Bhatt, S. Yusuf, 2018, International journal of stroke : official journal of the International Stroke Society.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2017, The Canadian journal of cardiology.

ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction

Raymond C. Schneider, R. Collins, M. Keltai, 1995, The Lancet.

Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation

S. Yusuf, Á. Avezum, L. Piegas, 1998, The Lancet.

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina

S. Yusuf, M. Keltai, B. Lewis, 2001 .

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.

S. Yusuf, M. Keltai, J. Varigos, 2001, Journal of the American College of Cardiology.

The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina.

S. Yusuf, Á. Avezum, M. Keltai, 1999, The American journal of cardiology.

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

S. Yusuf, J. Bosch, G. Dagenais, 2021, European heart journal.

Rationale and Design of INTERSTROKE: A Global Case-Control Study of Risk Factors for Stroke

D. Xavier, Li-sheng Liu, P. López-Jaramillo, 2010, Neuroepidemiology.

Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial

Donnell, Eld, Deepak L. Bhatt, 2017 .

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The Canadian journal of cardiology.

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2022, European heart journal. Cardiovascular pharmacotherapy.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study

K. L. Bansal, J. J. Huang, Michael A. Rodriguez, 2018, The Lancet.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries

Steven Hawken, Salim Yusuf, Fernando Lanas, 2004 .

Immunogenicity and reactogenicity associated with an 18‐month booster dose of a new diphtheria‐tetanus‐whole cell pertussis vaccine

J. Varigos, J. Carlin, T. Nolan, 1998, Journal of paediatrics and child health.

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.

S. Yusuf, M. Keltai, B. Lewis, 2000, European heart journal.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.

K. L. Bansal, J. J. Huang, Michael A. Rodriguez, 2018, Lancet.